OptiNose (OPTN) Q4 2024 earnings summary

Executive summary

• XHANCE net revenue reached $22.4 million in Q4 2024 and $78.2 million for the full year, up 13% and 10% year-over-year, respectively.

• Prescription demand inflected upward in September 2024, with Q4 NRx up 12% and TRX up 23% sequentially from Q3 2024.

• Achieved first-ever positive income from operations in Q4 2024 at $0.4 million.

Financial highlights

• Q4 2024 net revenue: $22.4 million (up 13% year-over-year); full year 2024: $78.2 million (up 10%).

• Q4 2024 net loss: $0.4 million ($0.04/share); full year 2024 net loss: $21.5 million ($2.12/share), both improved from prior year.

• Cash and cash equivalents at year-end: $84.5 million.

• SG&A plus R&D expenses for 2024: $87.3 million, up from $85.1 million in 2023.

• Weighted average shares outstanding for 2024: 10.2 million.

Segment performance

• XHANCE prescriptions showed strong growth: NRx up 12% and TRX up 23% sequentially from Q3 to Q4 2024.